

PROGRESSIVE RETINAL ATROPHY – GR2

REPORT NO.: SA2019/71518/0409/24

Client Name: LIANE VAN DER HOVEN
 Kennel Name:
 Client Address: SUITE 69
 PRIVATE BAG X16
 7200
 Client Tel No.: 072 697 0841



Canine Name: **BONYL MAGIC WILLOW**
 Breed: **GOLDEN RETRIEVER**
 Microchip No.: **945000001729504** Registration No.: **ZA008981B17**
 Genetic Test: **PROGRESSIVE RETINAL ATROPHY – GR2**
 Result: **CLEAR**

PROGRESSIVE RETINAL ATROPHY – GR2 (PRA_GR2)

Progressive Retinal Atrophy (PRA) is a collective of genetic eye disorders that share similar symptoms. There are numerous mutations that cause PRA in various canine breeds. PRA_GR2 is a late onset PRA discovered in Golden Retrievers responsible for 30% of PRA cases.

This test detects a single adenine deletion at c.699 of the TTC8 gene causing a shift in the reading frame. PRA_GR2 is an autosomal recessive photoreceptor degenerative disease, where two copies of the mutation are required for an individual to be affected.

Downs et al 2014. A novel mutation in TTC8 is associated with progressive retinal atrophy in the golden retriever. Canine Genetics and Epidemiology 1(4).

SAMPLE TYPE: EDTA BLOOD AMPULE
 EXTRACTION METHOD: DNA EXTRACTION
 TEST TYPE: SANGER SEQUENCE DETECTION

BREEDING IMPLICATIONS

		MATERNAL CANDIDATE		
		CLEAR	CARRIER	AFFECTED
PATERNAL CANDIDATE	CLEAR	ALL CLEAR	50% CLEAR 50% CARRIER	ALL CARRIER
	CARRIER	50% CLEAR 50% CARRIER	25% CLEAR 50% CARRIER 25% AFFECTED	50% CARRIER 50% AFFECTED
	AFFECTED	ALL CARRIER	50% CARRIER 50% AFFECTED	ALL AFFECTED

Disclaimer: This report does not disregard the existence of any unknown or rare variant of TTC8 gene that may cause PRA, nor does it disregard the existence of any unknown or rare variant of any other gene that may cause or be associated with PRA in Golden Retrievers.



DISCLAIMER: IT IS THE SENDER'S RESPONSIBILITY TO ENSURE THE CORRECTNESS OF INFORMATION ACCOMPANYING SAMPLE(S). INQABA BIOTEC™ WARRANTS THE TESTS TO BE ACCURATE FOR THE SAMPLE(S) OBTAINED FROM THE INDIVIDUALS IDENTIFIED IN THIS REPORT. IN NO EVENT SHALL INQABA BIOTEC™ BE HELD LIABLE FOR UNINTENDED, SUBSTANTIAL OR SECONDARY DAMAGES OF ANY KIND.